Results 121 to 130 of about 932,600 (248)

Association of the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) Scores with Guideline Recommendations in Breast Cancer. [PDF]

Curr Oncol
Salman B, Yehia I, Al Sharqi H, Al Shidi R, Al Dhahri MA, Al Ghefeili S, Makhloufi M, Al Ajmi A, Al Farsi S, Al Kiyumi Z, Al Ishaq ZRR, Ayaad OA, Al Baimani K.   +12 more
europepmc   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Correction: PARP inhibitors‑associated thrombosis in patients with ovarian cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group. [PDF]

Clin Transl Oncol
Sánchez Cánovas M, López Robles J, García Verdejo FJ, Cacho Lavin D, Olivares H, Garrido Fernández A, Coma Salvans E, Quintanar Verduguez T, Salvador Coloma C, Fernández Garay D, Cumplido JD, Ferrer Pérez AI, Carbó Bagué A, Teigell Muñoz FJ, García López R, Martínez Marin A, Muñoz Martín AJ.   +16 more
europepmc   +1 more source

Patients' education through scientifically-popular material [PDF]

Archive of Oncology, 2002
Jovanović Biljana, Brzaković Predrag, Jovićević-Bekić Ana, Mirković Verica, Živković Rada, Delić Jela   +5 more
doaj   +1 more source

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

Molecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis, Jack V. Mills, Wojciech Niedzwiedz, Valentine M. Macaulay   +3 more
wiley   +1 more source

Flow Enabled Target Capture Halbach‐based magnetic enrichment increases circulating tumor cell capture from blood in metastatic cancer patients

Molecular Oncology, EarlyView.
Pair‐wise comparison of the CellSearch and FETCH enrichment technologies for circulating tumor cells (CTCs) from metastatic breast, prostate, and small cell lung cancer patients shows an increased capture of CTCs using FETCH enrichment. The clinical implementation of circulating tumor cells (CTCs) as a predictive tool for therapy efficacy in the ...
Michiel Stevens, Anouk Mentink, Tom Niessink, Frank Coumans, Leonie Mekenkamp, Ruchi Bansal, Jeroen Hiltermann   +6 more
wiley   +1 more source

Editorial: Progressive role of artificial intelligence in treatment decision-making in the field of medical oncology. [PDF]

Front Med (Lausanne)
Thalambedu N, Sivasubramanian BP, Gupta S, Balla M.   +3 more
europepmc   +1 more source

Supplementum 283: Abstracts of the Swiss Oncology & Hematology Congress (SOHC)

Swiss Medical Weekly
Swiss Society of Medical Oncology, Swiss Society of Hematology, Swiss Group for Clinical Cancer Research   +2 more
doaj   +1 more source

USP29‐regulated noncanonical stabilization of the hypoxia‐inducible factor‐α in aggressive prostate cancer

Molecular Oncology, EarlyView.
We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober, Leire Moreno‐Cugnon, Laura Martínez‐Pérez, Amaia Ercilla, Amaia Zabala‐Letona, Adrián Vicente‐Barrueco, Maider Fagoaga‐Eugui, Saioa Garcia‐Longarte, Blanca Calle‐Ciborro, Encarnación Pérez‐Andrés, Onintza Carlevaris, Sara Pozo, Isabel Mendizabal, Ugo Mayor, Arkaitz Carracedo, Violaine Sée, Edurne Berra   +16 more
wiley   +1 more source

Educational needs in neuro-oncology: Insights from the European Society for Medical Oncology Central Nervous System Faculty Survey. [PDF]

Neurooncol Adv
Mirallas O, Cerretti G, Berghoff AS, Brandsma D, De Vos F, Furtner J, Galldiks N, Lombardi G, Lukacova S, Razis E, Tabatabai G, Le Rhun E, Franceschi E, Minniti G.   +13 more
europepmc   +1 more source